Literature DB >> 12539090

Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment.

Pierre Quartier1, Olivier Tournilhac, Christine Archimbaud, Leila Lazaro, Carine Chaleteix, Pascale Millet, Hélène Peigue-Lafeuille, Stéphane Blanche, Alain Fischer, Jean-Laurent Casanova, Philippe Travade, Marc Tardieu.   

Abstract

Treatment with the chimeric anti-CD20 monoclonal antibody rituximab induces rapid and long-lasting depletion of circulating B cells. We report the occurrence of enteroviral meningoencephalitis following rituximab therapy in 1 child with immune thrombocytopenia and in 1 adult patient with relapsed B cell lymphoma.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12539090     DOI： 10.1086/345746

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  22 in total

1.  Can primary immunodeficiencies help to provide insights into infectious risks of therapeutic antibodies?

Authors:  László Maródi; Jean-Laurent Casanova
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

Review 2.  Does rituximab increase the incidence of infectious complications? A narrative review.

Authors:  Theodoros Kelesidis; George Daikos; Dimitrios Boumpas; Sotirios Tsiodras
Journal:  Int J Infect Dis       Date:  2010-11-11       Impact factor: 3.623

3.  Enteroviral Encephalitis in a Child With CNS Relapse of Burkitt Leukemia Treated With Rituximab.

Authors:  Najma Shaheen; Francis Mussai
Journal:  J Pediatr Hematol Oncol       Date:  2019-01       Impact factor: 1.289

4.  [[Treatment of therapy resistant pemphigus vulgaris with rituximab and immunoglobulins].

Authors:  C Mühlhoff; M Megahed
Journal:  Hautarzt       Date:  2007-11       Impact factor: 0.751

5.  Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series.

Authors:  Nikolay Tzaribachev; Ina Koetter; Jasmin B Kuemmerle-Deschner; Joerg Schedel
Journal:  Cases J       Date:  2009-08-06

6.  Enteroviral T-cell encephalitis related to immunosuppressive therapy including rituximab.

Authors:  Nicolas Garzo-Caldas; Elena Ruiz-Sainz; Sara Vila-Bedmar; Sara Llamas-Velasco; Aurelio Hernández-Lain; Juan Ruiz-Morales; Dolores Folgueira-López; Alberto Villarejo-Galende
Journal:  Neurology       Date:  2017-06-23       Impact factor: 9.910

Review 7.  Emerging Infections and Pertinent Infections Related to Travel for Patients with Primary Immunodeficiencies.

Authors:  Kathleen E Sullivan; Hamid Bassiri; Ahmed A Bousfiha; Beatriz T Costa-Carvalho; Alexandra F Freeman; David Hagin; Yu L Lau; Michail S Lionakis; Ileana Moreira; Jorge A Pinto; M Isabel de Moraes-Pinto; Amit Rawat; Shereen M Reda; Saul Oswaldo Lugo Reyes; Mikko Seppänen; Mimi L K Tang
Journal:  J Clin Immunol       Date:  2017-08-07       Impact factor: 8.317

Review 8.  The long-term impact of rituximab for childhood immune thrombocytopenia.

Authors:  Nichola Cooper; James B Bussel
Journal:  Curr Rheumatol Rep       Date:  2010-04       Impact factor: 4.592

9.  Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease.

Authors:  Russell C Dale; Fabienne Brilot; Lisa V Duffy; Marinka Twilt; Amy T Waldman; Sona Narula; Eyal Muscal; Kumaran Deiva; Erik Andersen; Michael R Eyre; Despina Eleftheriou; Paul A Brogan; Rachel Kneen; Gulay Alper; Banu Anlar; Evangeline Wassmer; Kirsten Heineman; Cheryl Hemingway; Catherine J Riney; Andrew Kornberg; Marc Tardieu; Amber Stocco; Brenda Banwell; Mark P Gorman; Susanne M Benseler; Ming Lim
Journal:  Neurology       Date:  2014-06-11       Impact factor: 9.910

10.  Rituximab therapy for primary glomerulonephritis: Report on two cases.

Authors:  Fabrizio Fabrizi; Donata Cresseri; Giovanni B Fogazzi; Gabriella Moroni; Patrizia Passerini; Paul Martin; Piergiorgio Messa
Journal:  World J Clin Cases       Date:  2015-08-16       Impact factor: 1.337
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.